Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 46 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Osteoporosis [Clear All Filters]
Bone Health in Patients with Dyslipidemias: An Underestimated Aspect..
Int J Mol Sci. 23(3),
(2022). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2022). Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: an Endocrine Society Clinical Practice Guideline"..
J Clin Endocrinol Metab. 105(1),
(2020). The Mediterranean diet and menopausal health: An EMAS position statement..
Maturitas. 139, 90-97.
(2020). Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss..
Expert Opin Pharmacother. 20(9), 1123-1134.
(2019). Drug holidays in osteoporosis treatment: mind the gaps!.
Osteoporos Int. 30(12), 2523-2524.
(2019). New therapeutic targets for osteoporosis..
Maturitas. 120, 1-6.
(2019). Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide..
Maturitas. 107, 7-12.
(2018). Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review..
Endocrine. 60(3), 373-383.
(2018). The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study..
Haemophilia. 24(2), 316-322.
(2018). Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis..
Expert Opin Drug Saf. 17(4), 413-428.
(2018). Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management..
J Clin Endocrinol Metab. 102(10), 3621-3634.
(2017). Vitamin D and chronic diseases: the current state of the art..
Arch Toxicol. 91(1), 97-107.
(2017). Clinical vertebral fractures following denosumab discontinuation..
Endocrine. 54(1), 271-272.
(2016). Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis..
Osteoporos Int. 27(4), 1631-1643.
(2016). Investigational drugs for fracture healing: preclinical & clinical data..
Expert Opin Investig Drugs. 25(5), 585-96.
(2016). Minimally symptomatic hypocalcaemia unmasking celiac disease..
Scott Med J. 61(4), 195-196.
(2016).
(2016).
(2016). Bone disease in patients with haemophilia A and B--where are we now?.
Haemophilia. 21(1), 1-3.
(2015). Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis..
Expert Opin Investig Drugs. 24(2), 145-57.
(2015). Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk..
Expert Opin Drug Saf. 14(7), 1035-53.
(2015). Osteoporosis after renal transplantation..
Int Urol Nephrol. 47(3), 503-11.
(2015). Bone and fat interplay in inflammatory bowel disease: clinical implications and future perspectives..
Inflamm Bowel Dis. 20(11), E22.
(2014). Bone mineral density in men and children with haemophilia A and B: a systematic review and meta-analysis..
Osteoporos Int. 25(10), 2399-407.
(2014).